The gut peptide GLP-1 decreases motility in the antro-duodeno-jejunal region and inhibits the MMC in healthy subjects and IBS patients, as confirmed by reverse transcriptase PCR. The gene discussed is GCG; the disease is irritable bowel syndrome.